PTC (PTC) Analysts See $0.17 EPS, ARGOS THERAPEUTICS (ARGS) Sentiment Is 2.7

July 18, 2017 - By Kurt Siggers

Analysts expect PTC Inc (NASDAQ:PTC) to report $0.17 EPS on July, 19 after the close.They anticipate $0.02 EPS change or 10.53% from last quarter’s $0.19 EPS. PTC’s profit would be $19.87 million giving it 84.54 P/E if the $0.17 EPS is correct. After having $0.12 EPS previously, PTC Inc’s analysts see 41.67% EPS growth. The stock decreased 0.98% or $0.57 during the last trading session, reaching $57.49. About shares traded. PTC Inc (NASDAQ:PTC) has risen 57.23% since July 18, 2016 and is uptrending. It has outperformed by 40.53% the S&P500.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has market cap of $12.11 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

The stock decreased 2.44% or $0.007 during the last trading session, reaching $0.3. About shares traded. Argos Therapeutics Inc (ARGS) has declined 92.57% since July 18, 2016 and is downtrending. It has underperformed by 109.27% the S&P500.

Analysts await Argos Therapeutics Inc (NASDAQ:ARGS) to report earnings on August, 9. They expect $-0.13 earnings per share, up 72.92% or $0.35 from last year’s $-0.48 per share. After $-0.58 actual earnings per share reported by Argos Therapeutics Inc for the previous quarter, Wall Street now forecasts -77.59% EPS growth.

Wall Street Associates holds 0.27% of its portfolio in Argos Therapeutics Inc for 82,850 shares. Wasatch Advisors Inc owns 3.25 million shares or 0.24% of their US portfolio. Moreover, Altrinsic Global Advisors Llc has 0.03% invested in the company for 172,505 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. American International Group Inc, a New York-based fund reported 6,131 shares.

Ratings analysis reveals 0 of Argos Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Argos Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ARGS was included in 2 notes of analysts from February 22, 2017. The company was downgraded on Wednesday, February 22 by JMP Securities. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) earned “Mkt Perform” rating by FBR Capital on Wednesday, February 22.

Among 10 analysts covering PTC (NASDAQ:PTC), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. PTC had 21 analyst reports since July 30, 2015 according to SRatingsIntel. Sterne Agee CRT initiated PTC Inc (NASDAQ:PTC) on Wednesday, September 9 with “Neutral” rating. Zacks downgraded the shares of PTC in report on Tuesday, August 18 to “Hold” rating. Barclays Capital maintained the stock with “Overweight” rating in Thursday, July 30 report. The rating was maintained by Wedbush on Monday, September 21 with “Buy”. Brean Capital initiated the stock with “Buy” rating in Friday, October 7 report. Goldman Sachs initiated PTC Inc (NASDAQ:PTC) on Friday, November 4 with “Buy” rating. The stock of PTC Inc (NASDAQ:PTC) earned “Outperform” rating by Wedbush on Thursday, October 27. The stock of PTC Inc (NASDAQ:PTC) earned “Overweight” rating by KeyBanc Capital Markets on Thursday, October 8. The stock has “Outperform” rating by CLSA on Thursday, August 6. As per Thursday, October 8, the company rating was initiated by Pacific Crest.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: